ClinicalTrials.gg

Program

SHR-3079

A development code. Also written as “SHR-3079 Injection”.

Its studies are mostly in Lymphoma, B-Cell, led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Jun 16, 20261 company-led study, 1 open or runningNext primary completion: Dec 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningphase 1since Jun 16, 2026Jun 16, 2026Dec 2027phase 1 · NCT07661537
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-3079, phase 1, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 16, 2026First study: phase 1 study in Lymphoma, B-CellFirst studyNCT07661537 · 90 planned · China

Ahead

  1. Dec 2027Primary completion: phase 1 study in Lymphoma, B-CellNCT07661537

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07661537Lymphoma, B-Cell · China1RecruitingDec 202790

How it is read

Names in the registry

  • “SHR-3079 Injection”, 1 entry

Codes read as this program: SHR3079.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.